Latuda (lurasidone; Sumitomo Dainippon/Angelini) Drug Overview 2019

Report
39 Pages
March 2019
Region: Global
Citeline
ID: 4533521

Drug Overview
Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the synaptic reuptake of dopamine and serotonin, Latuda helps to normalize brain activity and reduce schizophrenia symptoms.

In 2011, Sumitomo Dainippon and Takeda entered into an agreement for the joint development and commercialization of Latuda in the EU (except for in the UK, where Sumitomo Dainippon retained exclusive rights), for the treatment of schizophrenia and bipolar disorder. Takeda terminated this alliance in May 2015, with all rights transferring back to Sumitomo Dainippon’s subsidiary Sunovion Pharmaceuticals. In November 2017, Sumitomo Dainippon announced a partnership with Angelini for the marketing and commercialization of Latuda in 29 European countries. While Sumitomo Dainippon will continue to supply Latuda in some EU countries including the UK, Angelini is now responsible for Latuda’s expansion to other countries. Latuda’s launch in Italy at the end of 2017 marked the first fruits of this strategic partnership.

Latuda has not yet been approved in Japan, but is in Phase III development for bipolar depression and schizophrenia. Sumitomo Dainippon plans to apply for manufacturing and marketing approval of Latuda in Japan in 2019. In the EU, Latuda is only approved for the treatment of schizophrenia.

OVERVIEW

Drug Overview
Product Profiles
Latuda: Depression
Latuda: Bipolar disorder
Latuda: Schizophrenia

LIST OF FIGURES

Figure 1: Latuda for bipolar disorder – SWOT analysis
Figure 2: The author's drug assessment summary for Latuda in bipolar disorder
Figure 3: The author's drug assessment summary for Latuda in bipolar disorder
Figure 4: Latuda for schizophrenia – SWOT analysis
Figure 5: The author's drug assessment summary of Latuda for schizophrenia
Figure 6: The author's drug assessment summary of Latuda for schizophrenia
Figure 7: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26

LIST OF TABLES

Table 1: Latuda drug profile
Table 2: Latuda Phase III data in depression
Table 3: Latuda for depression – SWOT analysis
Table 4: Latuda bipolar disorder indication approvals
Table 5: Latuda drug profile
Table 6: Overview of pivotal Phase III PREVAIL trials of Latuda in adults with bipolar depression
Table 7: Adverse reactions in =5% of Latuda-treated adult patients in bipolar depression studies
Table 8: Overview of the Phase III ILLUMINATE trial of Latuda in adolescents and children with bipolar depression
Table 9: Adverse reactions in =5% of Latuda-treated pediatric patients in bipolar depression studies
Table 10: Overview of key Japanese clinical trial data for Latuda in bipolar disorder
Table 11: Overview of clinical trial data for Latuda in maintenance treatment of bipolar I disorder
Table 12: Latuda drug profile
Table 13: Latuda pivotal trial data in schizophrenia
Table 14: Latuda other late-phase trial data in schizophrenia
Table 15: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26

Table of Contents

Related Topics

Related Reports

Lurasidone Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

Lurasidone (CAS 367514-87-2) Global Market Research Report 2024

Schizophrenia Market Insight, Epidemiology And Market Forecast - 2034

Schizophrenia Drugs Market Size, Share and Trends Analysis Report by Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), Treatment, Distribution Channels, and Region 2024-2030

Schizophrenia Market Report and Forecast 2024-2032